Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Symrise in connection with its mandatory offer on Probi
Mandate

Vinge represents Symrise in connection with its mandatory offer on Probi

February 06, 2014

Symrise AG has, after having acquired shares corresponding to approximately 30.03 per cent of the votes in Probi AB (publ), launched a mandatory offer to the shareholders in Probi, with an offered price of SEK 40.10 per share. Vinge represents Symrise in connection with the mandatory offer.

Symrise is a global supplier of fragrances, flavourings, cosmetic, active ingredients, and raw materials as well as functional ingredients. The company’s share is listed on the Frankfurt Stock Exchange and the market capitalisation of Symrise is EUR 4 billion.

Probi is a research-driven biotechnology company focused on the global probiotics market. Through Probi’s research Probi has developed probiotics with well-documented beneficial health effects. The company’s share is listed on NASDAQ OMX Stockholm, Small cap and the market capitalisation of Probi is approximately MSEK 375.

Vinge’s team primarily consists of Jesper Schönbeck, Oskar Belani, Joakim Hagberg and Sabina Börjesson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025